UNITED STATES SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C.

FORM D

OMB APPROVAL
OMB Number: 3235-0076
Estimated Average burden hours per response: 4.0
Notice of Exempt Offering of Securities


1. Issuer's Identity
CIK (Filer ID Number) Previous Name(s)   o None Entity Type
0000737207
NASTECH PHARMACEUTICAL CO. INC.
Marina Biotech, Inc.
MDRNA, Inc.
NASTECH PHARMACEUTICAL CO INC
 
x Corporation
o Limited Partnership
o Limited Liability Company
o General Partnership
o Business Trust
o Other
Name of Issuer
  Adhera Therapeutics, Inc.
Jurisdiction of Incorporation/Organization
DELAWARE
 
Year of Incorporation/Organization
  x Over Five Years Ago
  o Within Last Five Years (Specify Year)  
  o Yet to Be Formed  



2. Principal Place of Business and Contact Information
Name of Issuer  
  Adhera Therapeutics, Inc.  
Street Address 1 Street Address 2
  4721 EMPEROR BLVD.   SUITE 350
City State/Province/Country ZIP/Postal Code Phone No. of Issuer
  DURHAM   NORTH CAROLINA   27703   919-578-5901  



3. Related Persons
Last Name First Name Middle Name
Phelan Nancy
Street Address 1 Street Address 2
c/o Adhera Therapeutics, Inc. 4721 EMPEROR BLVD., SUITE 350
City State/Province/Country ZIP/Postal Code
DURHAM NORTH CAROLINA 27703
Relationship: x Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 
Last Name First Name Middle Name
Hacksell Uli
Street Address 1 Street Address 2
c/o Adhera Therapeutics, Inc. 4721 EMPEROR BLVD., SUITE 350
City State/Province/Country ZIP/Postal Code
DURHAM NORTH CAROLINA 27703
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 
Last Name First Name Middle Name
Blech Issac
Street Address 1 Street Address 2
c/o Adhera Therapeutics, Inc. 4721 EMPEROR BLVD., SUITE 350
City State/Province/Country ZIP/Postal Code
DURHAM NORTH CAROLINA 27703
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 
Last Name First Name Middle Name
Williams Donald A.
Street Address 1 Street Address 2
c/o Adhera Therapeutics, Inc. 4721 EMPEROR BLVD., SUITE 350
City State/Province/Country ZIP/Postal Code
DURHAM NORTH CAROLINA 27703
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 
 
Last Name First Name Middle Name
Boris Tim
Street Address 1 Street Address 2
c/o Adhera Therapeutics, Inc. 4721 EMPEROR BLVD., SUITE 350
City State/Province/Country ZIP/Postal Code
DURHAM NORTH CAROLINA 27703
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 
Last Name First Name Middle Name
Emerson Erik
Street Address 1 Street Address 2
c/o Adhera Therapeutics, Inc. 4721 EMPEROR BLVD., SUITE 350
City State/Province/Country ZIP/Postal Code
DURHAM NORTH CAROLINA 27703
Relationship: o Executive Officer x Director o Promoter
Clarification of Response (if Necessary)
 
 


4. Industry Group
o Agriculture   Health Care o Retailing
  Banking & Financial Services   o Biotechnology o Restaurants
  o Commercial Banking   o Health Insurance   Technology
  o Insurance   o Hospitals & Physicians   o Computers
  o Investing   x Pharmaceuticals   o Telecommunications
  o Investment Banking   o Other Health Care   o Other Technology
  o Pooled Investment Fund

        Travel
  o Other Banking & Financial Services o Manufacturing   o Airlines & Airports
  Real Estate   o Lodging & Conventions
  o Commercial   o Tourism & Travel Services
  o Construction   o Other Travel
  o REITS & Finance o Other
  o Residential  
  o Other Real Estate  
o Business Services  
  Energy  
  o Coal Mining  
  o Electric Utilities  
  o Energy Conservation  
  o Environmental Services  
  o Oil & Gas  
  o Other Energy  


5. Issuer Size
Revenue Range Aggregate Net Asset Value Range
o No Revenues o No Aggregate Net Asset Value
o $1 - $1,000,000 o $1 - $5,000,000
o $1,000,001 - $5,000,000 o $5,000,001 - $25,000,000
o $5,000,001 - $25,000,000 o $25,000,001 - $50,000,000
o $25,000,001 - $100,000,000 o $50,000,001 - $100,000,000
o Over $100,000,000 o Over $100,000,000
x Decline to Disclose o Decline to Disclose
o Not Applicable o Not Applicable


6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)
o Rule 504(b)(1) (not (i), (ii) or (iii)) o Rule 505
o Rule 504 (b)(1)(i) x Rule 506(b)
o Rule 504 (b)(1)(ii) o Rule 506(c)
o Rule 504 (b)(1)(iii) o Securities Act Section 4(a)(5)
  o Investment Company Act Section 3(c)

7. Type of Filing
x New Notice Date of First Sale   2019-06-28 o First Sale Yet to Occur
o Amendment

8. Duration of Offering
Does the Issuer intend this offering to last more than one year? o Yes x No

9. Type(s) of Securities Offered (select all that apply)
o Pooled Investment Fund Interests o Equity
o Tenant-in-Common Securities x Debt
o Mineral Property Securities o Option, Warrant or Other Right to Acquire Another Security
o Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security o Other (describe)
   


10. Business Combination Transaction
Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer? o Yes x No
 
Clarification of Response (if Necessary)  
   

11. Minimum Investment
Minimum investment accepted from any outside investor $   10000   USD

12. Sales Compensation
Recipient Recipient CRD Number o None
  Maxim Group LLC   120708
(Associated) Broker or Dealer x None (Associated) Broker or Dealer CRD Number x None
       
Street Address 1 Street Address 2
  405 LEXINGTON AVE.    
City State/Province/Country ZIP/Postal Code
  NEW YORK   NEW YORK   10174
State(s) of Solicitation o All States x Foreign/Non-US
  ARIZONA
  CALIFORNIA
  COLORADO
  CONNECTICUT
  FLORIDA
  IDAHO
  ILLINOIS
  INDIANA
  KENTUCKY
  MASSACHUSETTS
  MINNESOTA
  MISSOURI
  NEVADA
  NEW JERSEY
  NEW YORK
  NORTH CAROLINA
  PENNSYLVANIA
  SOUTH CAROLINA
  WISCONSIN
  PUERTO RICO
 
 



13. Offering and Sales Amounts
Total Offering Amount $   7000000   USD o Indefinite
Total Amount Sold $   3239400   USD  
Total Remaining to be Sold $   3760600   USD o Indefinite
 
Clarification of Response (if Necessary)
   


14. Investors
o Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors,
Number of such non-accredited investors who already have invested in the offering
 
  Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering: 45


15. Sales Commissions & Finders' Fees Expenses
Provide separately the amounts of sales commissions and finders' fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.
Sales Commissions $   323940   USD x Estimate
Finders' Fees $   0   USD o Estimate
 
Clarification of Response (if Necessary)
  Maxim will also receive additional commissions on any future sales in the offering.


16. Use of Proceeds
Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.
  $   0   USD o Estimate
 
Clarification of Response (if Necessary)
  A Portion of the proceeds may be used for general corporate purposes, including to pay salaries of some related persons listed in Item 3.

Signature and Submission
Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.
Terms of Submission  
  In submitting this notice, each Issuer named above is:  
 
  • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, the information furnished to offerees.
  • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the Issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against it in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
  • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).
 
 
  Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.
  For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer Signature Name of Signer Title Date
Adhera Therapeutics, Inc. /s/ Nancy R. Phelan Nancy R. Phelan Chief Executive Officer 2019-07-11

Adhera Therapeutics (CE) (USOTC:ATRX)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Adhera Therapeutics (CE).
Adhera Therapeutics (CE) (USOTC:ATRX)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Adhera Therapeutics (CE).